Brain Biomarkers Market

Brain Biomarkers Market Snapshot

The global brain biomarkers market is anticipated to exhibit growth at a CAGR of 14.3% in the forecast period from 2022 to 2032. It is set to reach US$ 8.3 Billion in 2022 and US$ 11.5 Billion in 2032. The rising prevalence of various neurological diseases, such as brain tumors, migraines, epilepsy, and dementia is projected to drive the sales of brain biomarkers in future years.

Biomarkers are referred to as molecules that indicate the presence of a dysfunction or disease. These are becoming increasingly important for monitoring disease progression, selecting the best treatments, and confirming diagnoses.

Neurological biomarkers are mainly present in Cerebrospinal Fluid (CSF) and rarely in blood. These can be studied by using CSF, but require an invasive lumbar puncture procedure.

Biomarker signatures are considered to be another powerful tool for studying neurological conditions and diseases. These are detected with the help of panels of high-quality antibodies.

The development of genomic biomarkers is projected to create new opportunities for the introduction of diagnostics that are based on a person’s specific genetic variations. Genomic biomarkers are also expected to help in the creation of personalized medicines.

Which are Some Major Factors Spurring Growth of the Brain Biomarkers Market

The ongoing technological advancement in the field of biomarkers and the emergence of biomarker signatures are expected to make neurological diseases more treatable. This is further expected to result in the early diagnosis, faster drug development, and non-invasive testing.

The launch of digital biomarkers by key players is set to deliver numerous pharmaceutical companies supplemental and contextual information to conclude clinical trials efficiently. Besides, government funding to accelerate research and development activities in various countries is expected to propel the demand for brain biomarkers in the assessment period.

Which Factors May Restrain the Brain Biomarkers Market Growth

The usage of brain biomarkers is limited to researchers for better understanding the disease progression. Several pharmaceutical and pathology companies worldwide are also using these to rapidly develop new therapeutics for neurodegenerative disorders. The lack of availability of commercial or direct-to-consumer tests may hamper the brain biomarkers market size in the near future.

Why is North America Projected to Dominate the Brain Biomarkers Market

North America is anticipated to lead in terms of the brain biomarkers market share during the forthcoming years. This growth is attributable to the rising research funding by regulatory bodies and the surging acceptance of biomarkers for drug development purposes in the U.S. and Canada.

The increasing prevalence of various neurological diseases across these developed countries is another significant factor that is estimated to augur well for the market.

As per the Centers for Disease Control and Prevention (CDC), at present, nearly 5.8 million people have Alzheimer’s disease in the U.S. Cases of Alzheimer’s disease are expected to reach 14 million by 2060 in the country. These numbers are projected to grow at a fast pace, thereby propelling the North America market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is the Asia Pacific Brain Biomarkers Market Progressing

Asia Pacific is likely to exhibit a CAGR of 15.4% in the forecast period from 2022 to 2032. The rising number of clinical trials that are being conducted in China, Japan, India, and South Korea is projected to drive the Asia Pacific brain biomarkers market growth in future years.

The surging demand for targeted drugs to treat conditions associated with the central nervous system is another vital factor that is anticipated to augment the growth in the regional market. According to the National Health Portal, in India, the prevalence of dementia is set to be around 2.7%. This condition poses a great challenge in the country owing to the surging geriatric population. This factor is also expected to fuel the regional market.

Market Competition

Majority of the key players operating in the global market are striving to incorporate the latest technologies to make it easier for researchers to track the condition of the brain by measuring its molecules. They are consistently developing innovative brain testing methods to provide new treatment options and enable faster diagnosis. Meanwhile, a few other key players are aiming to invest huge sums in clinical trials to boost new product development.

Some of the leading companies present in the global brain biomarkers market include Siemens Healthineers, Electrical Geodesics, Lifesign LLC, Advanced Brain Monitoring, BrainScope, GE Healthcare, Johnson & Johnson, Natus Medical, F. Hoffmann-La Roche Ltd., Qiagen N.V., Nexus-DX, and NeuroVista among others.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope

Key Segments Profiled in the Brain Biomarkers Industry Survey

By Product Type:

• Biomarker Test Kits
• Biomarker Analyzers

By Disease Indication:

• Stroke
• MND & ALS
• Alzheimer’s Disease & Other Dementias
• Parkinson’s Disease
• Huntington’s Disease

By Application:

• Diagnosis
• Drug Discovery and Development
• Others

By End User:

• Hospitals
• Research Laboratories
• Ambulatory Surgical Centers
• Diagnostic Laboratories

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East and Africa